Emalex Biosciences Inc.

This program gives children, teens, and adults aged 6 to 50 with Tourette's disorder early access to the study drug ecopipam before it is approved for sale. The main goals are to check if the drug is safe and tolerable over the long term, and to see if it improves quality of life…